Evotec

Evotec, IR Pharma partner for respiratory disease drug discovery

Friday, February 17, 2012 01:41 PM

Evotec and IR Pharma have formed an exclusive strategic alliance to provide integrated drug discovery solutions to pharmaceutical and biotech companies in the field of respiratory diseases.

More... »


Evotec partners with Roche in $820 million Alzheimer’s deal

Tuesday, September 6, 2011 01:10 PM

Evotec has signed a new agreement with partner Roche to develop a compound with potential in Alzheimer's disease, replacing an antidepressant program which was dropped in May, according to PharmaTimes.

More... »


Evotec acquires Kinaxo Biotechnologies

Tuesday, April 19, 2011 11:28 AM

Germany-based Evotec has acquired of Kinaxo Biotechnologies, a drug discovery business with particular expertise in oncology. Completion of the deal gives Evotec access to technologies in drug discovery, efficacy, response predication, and safety assessment.

More... »

Evotec collaborates with Harvard and HHMI

Friday, March 11, 2011 01:45 PM

Evotec announced a research collaboration with Harvard University and the Howard Hughes Medical Institute (HHMI) aimed at discovering and developing new treatments in diabetes, according to a Reuters report.

More... »


CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks worldwide toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs